17-beta-estradiol
brca2 Mutation Carrier
City of Hope Medical CenterPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the brca2 Mutation Carrier cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Letrozole UNICANCER | Phase 3 | BB |
pf-01367338 Cancer Research UK | Phase 2 | B |
AG-014699 Cancer Research UK | Phase 2 | B |
TESTOSTERONE UNDECYLATE City of Hope Medical Center | Phase 2 | CCC |
Deslorelin City of Hope Medical Center | Phase 2 | CCC |
Fenretinide University of Arizona | N/A | D |
Dfn-15 University of Alabama at Birmingham | N/A | D |
Same molecule, other indications
17-beta-estradiol is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →